Yatharth Hospitals Q1 FY27: Record Revenue, New Hospitals Scale, Margins Wait for Full Ramp

Yatharth Hospital and Trauma Care Services Limited started FY27 with its strongest quarter so far. Consolidated revenue from operations rose to Rs 3,927 million in Q1 FY27, up 51.5% year on year and 14.9% sequentially. EBITDA increased to Rs 917 million, up 39% year on year, while profit after tax came in at Rs 454 million.

The quarter was shaped by two forces moving in parallel. Mature hospitals in the Noida cluster and Jhansi-Orchha continued to grow steadily, while recently added hospitals began contributing a larger share of revenue. This mix shift supported revenue momentum, but it also diluted reported margins as newer units are still in ramp-up.

What drove the quarter: mature base plus a faster scaling new cohort

Management highlighted that the newer hospitals in Greater Faridabad, New Delhi Model Town, Faridabad Sector-20, and Agra together contributed Rs 1,067 million in Q1, or 27% of group revenue. In the same period, the existing hospitals delivered 22% year-on-year growth, supported by improving inpatient volumes and high occupancy at key locations.

Operational metrics were steady, with occupancy reported at 68% and ARPOB at Rs 34,758, up 7% year on year. The company also reported a lower average length of stay at 3.73 days, which management linked to a higher surgical mix at newer hospitals and a lower share of government patients in these facilities.

At a hospital level, the company disclosed that premium NCR hospitals reached high realisations. On the earnings call, management stated that Noida Extension and New Delhi crossed the Rs 50,000 ARPOB mark during Q1, while Greater Noida was around Rs 43,000 and Faridabad Sector-20 was approaching Rs 40,000. Jhansi remained at a materially lower ARPOB of around Rs 13,000.

Financial snapshot: strong top line, margin drag from ramp-up and higher fixed costs

While revenue and EBITDA were at record levels, profitability ratios were softer. EBITDA margin stood at 23.3% compared to 25.4% in Q1 FY26. PAT margin dropped to 11.6% from 16.2% a year ago. The P&L also shows rising fixed costs linked to recent capacity additions. Depreciation and amortisation nearly doubled to Rs 282 million, and finance costs rose to Rs 66 million.

Management emphasised an adjusted EBITDA margin of 28.1% by excluding ramp-up losses from Model Town and Faridabad Sector-20. This framing indicates the profitability of the mature base, but it also underlines that consolidated margins will depend on how quickly these new assets move from breakeven to steady-state profitability.

New hospitals: early validation of the acquisition playbook

A key highlight of the quarter was Faridabad Sector-20 achieving EBITDA breakeven in nine months. The investor presentation reported Q1 FY27 revenue of about Rs 33 crore and a latest monthly run-rate of about Rs 12 to 13 crore, with ARPOB around Rs 40,000. Management also said this unit is running with more than 90% cash and TPA mix.

New Delhi Model Town, positioned as a premium NCR entry, reported Q1 revenue of about Rs 19 crore and an ARPOB close to Rs 50,000. Management guided that EBITDA breakeven is expected in the second half of the year, and clarified on the call that this hospital remains on track versus its own 15 to 17 month breakeven plan.

Agra appears to have scaled faster on profitability. The company reported Q1 revenue of about Rs 24 crore with EBITDA above 20% in its first full quarter of integration. The hospital is also highlighted as having robotic capabilities, including a Da-Vinci X robot and a Velys ortho robot, with more than 150 robotic surgeries completed.

This early performance matters because it supports the strategic premise management is selling to investors: acquire or add beds, ramp them quickly, shift payer mix toward cash and private insurance, and use the mature base to fund the next expansion.

Capacity roadmap: moving from 2,800 plus beds toward 5,000

The company disclosed a network of 9 hospitals and 2,800 plus beds including the upcoming Gurugram facility. The stated capacity target is 5,000 beds, with management repeatedly indicating that it may be achieved earlier than the originally communicated three-year timeline.

The Gurugram asset is an under-construction 250-bed hospital in Sector 40. The presentation notes a 100% stake acquisition cost of Rs 100 crore, with an additional outlay including medical equipment of Rs 100 crore, implying a total proposed outlay of Rs 200 crore. Operationalisation is expected by Q1 FY28, and management has described ARPOB potential of around Rs 50,000 plus.

In addition, management guided that brownfield additions of 450 beds are planned across Greater Noida and Noida Extension. On the earnings call, they stated these beds are expected to start coming live in about 15 to 18 months, with a phased rollout where about 200 beds could be earlier and the remaining about 250 beds in roughly 18 to 19 months.

Capital intensity is also rising. Management stated that capex per bed for the next 1,800 beds is expected to be around Rs 75 to 80 lakhs, citing higher land prices and higher-end medical equipment, and noting that Gurugram itself is close to Rs 1 crore per bed.

Mix and monetisation: the ARPOB thesis and the payer mix push

The company continues to push a mix-shift strategy. It wants the network to progressively tilt towards higher ARPOB hospitals in Delhi NCR. In Q1 FY27, management stated that the premium NCR hospitals at Noida Extension and New Delhi crossed the Rs 50,000 ARPOB mark, and they positioned Gurugram and Faridabad Sector-20 as future candidates to reach similar benchmarks over time.

A significant enabler for this strategy is payer mix. Management acknowledged that the company is intentionally reducing government business in select hospitals. On the call, they said government payer mix is around 40% at the company level, but at newer hospitals government share is not more than 10%. They also explained that they restricted government business at Noida Extension, which impacted occupancy modestly but aligns with their objective of improving payer mix and realisations.

International patient flow is another lever management wants to build. They highlighted opening a Yatharth information centre in Uzbekistan and referenced partnerships and outreach across Africa, Asia, and the Middle East. While no quantitative numbers were provided for international revenue contribution, management linked these efforts to better payer mix and higher ARPOB.

Costs, cash returns, and what investors should watch

The operating cost structure shows pressure points typical of a fast-expanding hospital chain. Employee expenses rose 61.7% year on year and other expenses rose 65.4%, in part reflecting new hospitals and higher specialist costs. On the call, management stated that other expenses rose due to higher specialist doctor charges, quantified as about a 2% change quarter on quarter.

On shareholder returns, the board declared its first interim dividend at 5% of face value. Management also discussed ESOP grants and a new ESOP scheme to attract and retain talent.

For investors, the next few quarters will likely hinge on three operating outcomes. First is how quickly Model Town and Faridabad Sector-20 move from breakeven to mid-teen margins. Second is whether occupancy lifts in Greater Noida and Noida Extension while maintaining the premium payer mix approach. Third is the execution timeline for Gurugram and brownfield capacity additions.

Management provided directional guidance, stating that FY27 revenue growth should exceed last year’s growth and that the company is targeting an EBITDA margin of around 24% for the full year. They also guided for ARPOB growth of about 9% to 10% year on year for FY27.

Takeaways from Q1 FY27

Yatharth’s Q1 FY27 shows a company in the middle of scaling. The headline performance is strong, supported by a steady mature base and rapidly scaling acquisitions. The ramp-up playbook is already visible in Faridabad Sector-20’s fast breakeven and Agra’s quick margin uplift.

At the same time, consolidated margins remain in a transition phase because depreciation, interest, and ramp-up losses are rising with capacity. If the company delivers on occupancy ramp, premium payer mix, and the commissioning timeline for Gurugram and Noida cluster expansions, the quarter’s message could prove durable: growth is being created not only by adding beds, but also by improving the quality of revenue per bed.